NASDAQ$BCYC
Bicycle Therapeutics plc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported second quarter 2022 financial results and provided corporate update.
Bicycle Therapeutics reported its second quarter financial results, highlighting clinical progress across its pipeline and the expansion of its collaboration with Genentech. The company's cash and cash equivalents totaled $372.8 million as of June 30, 2022, providing a financial runway into 2025.
- Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II study of BT5528.
- Expansion of Genentech exclusive strategic collaboration, triggering a $10 million payment to Bicycle in Q3.
- Cash and cash equivalents of $372.8 million as of June 30, 2022, excludes $9.8 million UK R&D tax credit received in July and Genentech payment.
- Financial runway expected into 2025.
Headline financials
Revenue & EPS history
Bicycle · Revenue · Quarterly
$4.38M
Forward guidance
Bicycle Therapeutics anticipates continued advancement of its product candidates, including BT5528, BT8009 and BT7480, progression of its clinical trials, and expansion of its discovery efforts and early development pipeline.
Tailwinds
- Advancement of product candidates.
- Progression of clinical trials.
- Expansion of discovery efforts.
- Early development pipeline growth.
- Strong balance sheet.
Headwinds
- Risks to clinical trial site initiation.
- Patient enrollment and follow-up challenges.
- Uncertainties in clinical trials and development.
- Potential adverse effects from product candidates.
- Risk of inaccurate financial runway projections.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+1.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+19.3%
Q4 2019
Best reaction
-10.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +3.6% | -0.8% | |
| Q4 2025 | -4.2% | -13.9% | +1.8% | |
| Q3 2025 | +6.7% | -16.0% | -8.6% | |
| Q1 2025 | +6.1% | -13.6% | -4.0% | |
| Q4 2024 | -1.3% | -2.5% | -18.3% | |
| Q3 2024 | -5.5% | -2.2% | -15.1% | |
| Q2 2024 | -0.7% | +2.1% | -10.0% | |
| Q1 2024 | +1.6% | -4.6% | -8.3% | |
| Q4 2023 | +3.1% | +9.5% | +14.9% | |
| Q3 2023 | +1.2% | -0.7% | -2.3% | |
| Q2 2023 | +1.3% | -2.8% | -4.1% | |
| Q1 2023 | -0.4% | +2.5% | +15.7% | |
| Q4 2022 | -1.9% | -5.5% | -6.2% | |
| Q3 2022 | -3.2% | +0.8% | +29.6% | |
| Q2 2022 | +14.8% | +17.7% | +12.8% | |
| Q1 2022 | -10.8% | -22.6% | -33.6% | |
| Q4 2021 | -1.2% | -9.7% | -7.6% | |
| Q3 2021 | +0.7% | +2.5% | -6.8% | |
| Q2 2021 | +1.8% | +2.3% | +36.0% | |
| Q1 2021 | +1.9% | -1.3% | -5.5% | |
| Q4 2020 | +1.9% | +2.0% | +3.8% | |
| Q3 2020 | -1.5% | +3.1% | +5.2% | |
| Q2 2020 | -0.2% | +0.0% | +5.8% | |
| Q1 2020 | +0.7% | +6.6% | +23.2% | |
| Q4 2019 | +19.3% | +1.5% | -2.3% | |
| Q3 2019 | -4.2% | -7.7% | -4.8% | |
| Q2 2019 | +5.9% | +5.4% | -6.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro